The primary objective of this study was to evaluate the efficacy of zanubrutinib in participants with centrally confirmed relapsed or refractory MCL.
| Study Arm | Population | Intervention | Comparison | Outcome |
|---|---|---|---|---|
R/R MCL |
Zanubrutinib |
None |
Primary Endpoint: ORR (IRC) Key Secondary Endpoints: PFS, DoR, OS, safety |
